Trevi Therapeutics, Inc. announced it expects to receive $3 million in funding from New Enterprise Associates. The company entered into a securities purchase agreement with existing investor New Enterprise Associates 16, L.P., a fund managed by New Enterprise Associates. The announced funding is expected to be provided under that securities purchase agreement. The article does not disclose Trevi's product details, operating metrics, or use of proceeds. No additional investors, financing terms, past rounds, founding year, or location were reported in the article. Trevi Therapeutics is a late-stage clinical development company focused on Nalbuphine ER, an oral extended‑release synthetic opioid with a dual mu receptor antagonist and kappa receptor agonist mechanism intended to treat chronic pruritus. The company is pursuing development in prurigo nodularis and uremic pruritus, conditions for which there are no approved therapies in the US or EU. Trevi announced positive blinded Phase 2 results in prurigo nodularis and a statistically significant reduction in itch intensity in a Phase 2/3 trial in uremic pruritus. It also completed six‑month and one‑year open‑label extension studies that showed tolerability and durability of effect. The company recently completed a $50.5M Series C financing to advance Nalbuphine ER into pivotal studies. Trevi was founded in 2011 and is headquartered in New Haven, Connecticut. Trevi Therapeutics is a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus conditions. The company is pursuing two clinical indications: uremic pruritus and prurigo nodularis, both of which currently have no approved therapies in the US or EU. Nalbuphine ER is an oral extended-release opioid with a dual opioid receptor agonist/antagonist mechanism that has shown efficacy in animal studies and human clinical trials. Trevi initiated a pivotal trial in uremic pruritus in mid-2014 and expected to report results in mid-2015. The company believes Nalbuphine ER could have broad utility in treating chronic pruritus. Trevi closed a $15 million senior secured term loan to support completion of its ongoing clinical trials. Trevi Therapeutics is developing Nalbuphine ER, an oral extended-release opioid with a dual agonist/antagonist mechanism, for chronic pruritus. The company is pursuing two indications: uremic pruritus and prurigo nodularis, for which there are no approved therapies in the US or EU. Trevi is continuing enrollment in a pivotal uremic pruritus trial expected to enroll approximately 360 patients in the U.S. and plans to initiate European sites by year-end. The company also anticipates initiating a pivotal trial in prurigo nodularis this quarter. Nalbuphine ER has shown efficacy in animal studies and human clinical trials, and Trevi expects top-line results from the uremic pruritus trial in mid-2015. Financially, Trevi completed a $26 million Series B financing (second and final closing of $11 million) led by TPG Biotech and existing angel investors. Trevi Therapeutics was founded in 2011 and is based in New Haven, CT. The company is developing T111, an oral extended‑release opioid with a dual agonist/antagonist mechanism of action that has shown efficacy in animal and human studies. Trevi is pursuing uremic pruritus as its lead indication, a persistent and debilitating itching in dialysis patients for which there are no approved therapies in the U.S. or Europe. With a $10 million Series A from TPG Biotech, Trevi intends to advance T111 into clinical development for uremic pruritus. Prior to the Series A, the company received funding from angel investors and a seed investment from TPG Biotech to support preclinical testing, regulatory activities, initial clinical planning and IP prosecution. Trevi plans to initiate an efficacy clinical trial in uremic pruritus patients in the first quarter of 2014 and has TPG Biotech representatives on its board.

Total raised

$90M

Funding rounds

5

Latest round

Equity

Latest activity

Oct 2021